Galectin Therapeutics (NASDAQ: GALT) and Eiger Biopharmaceuticals (NASDAQ:EIGR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Risk & Volatility

Galectin Therapeutics has a beta of 2.54, meaning that its stock price is 154% more volatile than the S&P 500. Comparatively, Eiger Biopharmaceuticals has a beta of 2.55, meaning that its stock price is 155% more volatile than the S&P 500.

Insider and Institutional Ownership

10.8% of Galectin Therapeutics shares are held by institutional investors. Comparatively, 47.1% of Eiger Biopharmaceuticals shares are held by institutional investors. 38.8% of Galectin Therapeutics shares are held by company insiders. Comparatively, 28.8% of Eiger Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Galectin Therapeutics and Eiger Biopharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Galectin Therapeutics N/A -1,747.01% -160.00%
Eiger Biopharmaceuticals N/A -169.16% -95.71%

Analyst Recommendations

This is a breakdown of recent recommendations for Galectin Therapeutics and Eiger Biopharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galectin Therapeutics 0 1 3 0 2.75
Eiger Biopharmaceuticals 0 0 7 0 3.00

Galectin Therapeutics currently has a consensus price target of $6.25, suggesting a potential upside of 6.47%. Eiger Biopharmaceuticals has a consensus price target of $32.86, suggesting a potential upside of 105.36%. Given Eiger Biopharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Eiger Biopharmaceuticals is more favorable than Galectin Therapeutics.

Valuation and Earnings

This table compares Galectin Therapeutics and Eiger Biopharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Galectin Therapeutics N/A N/A -$21.43 million ($0.55) -10.67
Eiger Biopharmaceuticals N/A N/A -$47.08 million ($5.30) -3.02

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Eiger Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Eiger Biopharmaceuticals beats Galectin Therapeutics on 8 of the 11 factors compared between the two stocks.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company’s galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.

Eiger Biopharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc., formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema. Lonafarnib is an orally active inhibitor of farnesyl transferase that inhibits the prenylation step of HDV replication inside liver cells and blocks the ability of the virus to multiply. It is conducting over three Phase II clinical trials, which include LOnafarnib With and without Ritonavir (LOWR) HDV-2 (Ankara, Turkey), LOWR HDV-3 (NIH) and LOWR HDV-4 (Hannover, Germany). Exendin is in Phase II clinical studies for the treatment of hypoglycemia associated with bariatric surgery. Ubenimex is in Phase II clinical studies for the treatment of PAH and lymphedema.

Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.